Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
467.23
+9.55 (+2.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
September 29, 2023
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.
Via
Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
September 27, 2023
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an
Via
Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
September 27, 2023
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.
Via
Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
September 27, 2023
The company may have best-in-class autoimmune disease therapy under its roof.
Via
The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
September 27, 2023
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.
Via
Investor's Business Daily
The Latest Analyst Ratings for argenx
September 18, 2023
Via
Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
September 15, 2023
Via
Benzinga
What 20 Analyst Ratings Have To Say About argenx
August 31, 2023
Via
Benzinga
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
September 26, 2023
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.
Via
Investor's Business Daily
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 21, 2023
From
argenx SE
Via
GlobeNewswire
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
September 16, 2023
These stocks could lead if the market rallies.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
August 30, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
August 10, 2023
Via
Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
July 31, 2023
Via
Benzinga
Is Argenx Stock a Buy Now?
July 31, 2023
Good news keeps rolling in for the biotech.
Via
The Motley Fool
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
August 30, 2023
From
argenx SE
Via
GlobeNewswire
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market
August 19, 2023
Arista Networks and Dutch biotech Argenx lead this weekend's watch list.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023
From
argenx SE
Via
GlobeNewswire
Earnings Outlook For argenx
July 26, 2023
Via
Benzinga
argenx Unusual Options Activity
July 21, 2023
Via
Benzinga
Why Shares of Argenx Jumped This Week
July 21, 2023
The company's lead therapy showed progress in treating an autoimmune disorder.
Via
The Motley Fool
The Latest Analyst Ratings for argenx
July 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
July 31, 2023
Via
Benzinga
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
July 26, 2023
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week.
Via
Investor's Business Daily
argenx announces closing of global offering
July 24, 2023
From
argenx SE
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
July 24, 2023
Via
Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
July 21, 2023
But all the major indexes are at or near 15-month highs.
Via
Investor's Business Daily
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
July 20, 2023
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.